Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer

Journal of Controlled Release

Volumn 192, Issue , 2014, Pages 47-56

  Wang, Huixin ^a,b   Zhao, Yongxing ^b   Wang, Huiyuan ^a   Gong, Junbo ^c   He, Huining ^d   Shin, Meong Cheol ^e   Yang, Victor C ^a,d,e   Huang, Yongzhuo ^a,e  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b ZHENGZHOU UNIVERSITY   (China)

^c TIANJIN UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Breast cancer; Cell penetrating peptide; Doxorubicin; Low molecular weight protamine; Multidrug resistance; PLGA nanoparticle

Indexed keywords

DISEASES; DRUG DELIVERY; MAMMALS; NANOPARTICLES; ONCOLOGY; PEPTIDES; TUMORS;

BREAST CANCER; CELL-PENETRATING PEPTIDE; DOXORUBICIN; LOW MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; PLGA NANOPARTICLES;

COPOLYMERS;

CELL PENETRATING PEPTIDE; DOXORUBICIN; LOW MOLECULAR WEIGHT PROTAMINE; NANOCARRIER; POLYGLACTIN; PROTAMINE; UNCLASSIFIED DRUG; VERAPAMIL; NANOPARTICLE; ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT DISORDER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TUMOR LEVEL; DRUG UPTAKE; FATTY LIVER; HUMAN; HUMAN CELL; LIVER INJURY; LUNG HEMORRHAGE; LUNG INJURY; MCF 7 CELL LINE; MOUSE; MULTIDRUG RESISTANCE; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; SPLEEN INJURY; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CYTOTOXICITY TEST; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; DRUG RETENTION; IC50; IN VITRO STUDY; IN VIVO STUDY; NANOENCAPSULATION; PARTICLE SIZE; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BREAST; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; METABOLISM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; POLYGLYCOLIC ACID; PROTAMINES;

EID: 84904873394     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.06.051     Document Type: Article

References (41)

1. S.A. Eccles, E.O. Aboagye, S. Ali, A.S. Anderson, J. Armes, F. Berditchevski, J.P. Blaydes, K. Brennan, N.J. Brown, and H.E. Bryant Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer Breast Cancer Res. 15 2013 R92
2. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
3. T.R. Wilson, P.G. Johnston, and D.B. Longley Anti-apoptotic mechanisms of drug resistance in cancer Curr. Cancer Drug Targets 9 2009 307 319
4. D. Goren, A.T. Horowitz, D. Tzemach, M. Tarshish, S. Zalipsky, and A. Gabizon Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump Clin. Cancer Res. 6 2000 1949 1957 (Pubitemid 30305094)
5. Z.X. Zhou, Y.Q. Shen, J.B. Tang, M.H. Fan, E.A. Van Kirk, W.J. Murdoch, and M. Radosz Charge-reversal drug conjugate for targeted cancer cell nuclear drug delivery Adv. Funct. Mater. 19 2009 3580 3589
6. R.H. Grantab, and I.F. Tannock Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib BMC Cancer 12 2012 214
7. I.F. Tannock, C.M. Lee, J.K. Tunggal, D.S. Cowan, and M.J. Egorin Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy Clin. Cancer Res. 8 2002 878 884 (Pubitemid 34742121)
8. A.I. Minchinton, and I.F. Tannock Drug penetration in solid tumours Nat. Rev. Cancer 6 2006 583 592 (Pubitemid 44140857)
9. F. Marcucci, R. Berenson, and A. Corti Improving drug uptake and penetration into tumors: current and forthcoming opportunities Front. Oncol. 3 2013 161
10. Y. Huang, Y. Jiang, H. Wang, J. Wang, M.C. Shin, Y. Byun, H. He, Y. Liang, and V.C. Yang Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery Adv. Drug Deliv. Rev. 65 2013 1299 1315
11. Y. Huang, Y.S. Park, C. Moon, A.E. David, H.S. Chung, and V.C. Yang Synthetic skin-permeable proteins enabling needleless immunization Angew. Chem. Int. Ed. Engl. 49 2010 2724 2727
12. Y.X. Yang, Y.F. Jiang, Z. Wang, J.H. Liu, L. Yan, J.X. Ye, and Y.Z. Huang Skin-permeable quaternary nanoparticles with layer-by-layer structure enabling improved gene delivery J. Mater. Chem. 22 2012 10029 10034
13. H. He, J. Sheng, A.E. David, Y.M. Kwon, J. Zhang, Y. Huang, J. Wang, and V.C. Yang The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption Biomaterials 34 2013 7733 7743
14. Y. Huang, M. Shin, and V.C. Yang Cell-penetrating peptide enables nose-to-brain delivery of macromolecules. AAPS2009-003288 The AAPS (American Association of Pharmaceutical Scientists) Annual Meeting and Exposition, Los Angeles, California 2009
15. Q.Q. Guo, H.Y. Wang, Y.X. Zhao, H.X. Wang, F. Zeng, H.Y. Hua, Q. Xu, and Y.Z. Huang Cell-penetrating albumin conjugates for enhanced doxorubicin delivery Polym. Chem. 4 2013 4584
16. L.C. Chang, H.F. Lee, Z. Yang, and V.C. Yang Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization AAPS PharmSci. 3 2001 E17
17. L.C. Chang, J.F. Liang, H.F. Lee, L.M. Lee, and V.C. Yang Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity AAPS PharmSci. 3 2001 E18
18. L.M. Lee, L.C. Chang, S. Wrobleski, T.W. Wakefield, and V.C. Yang Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model AAPS PharmSci. 3 2001 E19
19. J.F. Liang, L. Zhen, L.C. Chang, and V.C. Yang A less toxic heparin antagonist - low molecular weight protamine Biochemistry (Mosc) 68 2003 116 120
20. B. Heurtault, P. Saulnier, B. Pech, J.E. Proust, and J.P. Benoit Physico-chemical stability of colloidal lipid particles Biomaterials 24 2003 4283 4300 (Pubitemid 36814076)
21. Y.J. Park, L.C. Chang, J.F. Liang, C. Moon, C.P. Chung, and V.C. Yang Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study FASEB J. 19 2005 1555 1557 (Pubitemid 41279029)
22. K. Cleal, L. He, P.D. Watson, and A.T. Jones Endocytosis, intracellular traffic and fate of cell penetrating peptide based conjugates and nanoparticles Curr. Pharm. Des. 19 2013 2878 2894
23. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234 (Pubitemid 43336035)
24. J. Liu, Y. Zhao, Q. Guo, Z. Wang, H. Wang, Y. Yang, and Y. Huang TAT-modified nanosilver for combating multidrug-resistant cancer Biomaterials 33 2012 6155 6161
25. X. Shuai, H. Ai, N. Nasongkla, S. Kim, and J. Gao Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery J. Control. Release 98 2004 415 426 (Pubitemid 39093952)
26. K. Kataoka, T. Matsumoto, M. Yokoyama, T. Okano, Y. Sakurai, S. Fukushima, K. Okamoto, and G.S. Kwon Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance J. Control. Release 64 2000 143 153 (Pubitemid 30035315)
27. L. Pan, Q. He, J. Liu, Y. Chen, M. Ma, L. Zhang, and J. Shi Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles J. Am. Chem. Soc. 134 2012 5722 5725
28. L. Pan, J. Liu, Q. He, L. Wang, and J. Shi Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles Biomaterials 34 2013 2719 2730
29. C.H. Heldin, K. Rubin, K. Pietras, and A. Ostman High interstitial fluid pressure - an obstacle in cancer therapy Nat. Rev. Cancer 4 2004 806 813 (Pubitemid 39331152)
30. N. Rohwer, and T. Cramer Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways Drug Resist. Updat. 14 2011 191 201
31. Y. Piao, Y. Liu, and X. Xie Change trends of organ weight background data in Sprague Dawley rats at different ages J. Toxicol. Pathol. 26 2013 29 34
32. S. Kizaka-Kondoh, M. Inoue, H. Harada, and M. Hiraoka Tumor hypoxia: a target for selective cancer therapy Cancer Sci. 94 2003 1021 1028 (Pubitemid 38035514)
33. O. Tredan, C.M. Galmarini, K. Patel, and I.F. Tannock Drug resistance and the solid tumor microenvironment J. Natl. Cancer Inst. 99 2007 1441 1454
34. X.B. Xiong, and A. Lavasanifar Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin ACS Nano 5 2011 5202 5213
35. U. Niesner, C. Halin, L. Lozzi, M. Gunthert, P. Neri, H. Wunderli-Allenspach, L. Zardi, and D. Neri Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides Bioconjug. Chem. 13 2002 729 736 (Pubitemid 34801114)
36. X. Sun, G. Niu, Y. Yan, M. Yang, K. Chen, Y. Ma, N. Chan, B. Shen, and X. Chen Phage display-derived peptides for osteosarcoma imaging Clin. Cancer Res. 16 2010 4268 4277
37. F. Lamoureux, G. Picarda, L. Garrigue-Antar, M. Baud'huin, V. Trichet, A. Vidal, E. Miot-Noirault, B. Pitard, D. Heymann, and F. Redini Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma Cancer Res. 69 2009 526 536
38. J. Kleeff, T. Ishiwata, A. Kumbasar, H. Friess, M.W. Buchler, A.D. Lander, and M. Korc The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer J. Clin. Invest. 102 1998 1662 1673 (Pubitemid 28516251)
39. K. Matsuda, H. Maruyama, F. Guo, J. Kleeff, J. Itakura, Y. Matsumoto, A.D. Lander, and M. Korc Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells Cancer Res. 61 2001 5562 5569 (Pubitemid 32694943)
40. C. Mundhenke, K. Meyer, S. Drew, and A. Friedl Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas Am. J. Pathol. 160 2002 185 194 (Pubitemid 34052279)
41. A. Faustino-Rocha, P.A. Oliveira, J. Pinho-Oliveira, C. Teixeira-Guedes, R. Soares-Maia, R.G. da Costa, B. Colaco, M.J. Pires, J. Colaco, R. Ferreira, and M. Ginja Estimation of rat mammary tumor volume using caliper and ultrasonography measurements Lab. Anim. (NY) 42 2013 217 224